FX-06 is a synthetic peptide with a broad spectrum of potential applications associated with endothelial barrier integrity, blood vessel permeability and inflammation

Potential applications include COVID-19, pandemic, chemical, biological, radiological and nuclear threats

Lexington, MA – March 3, 2021 — Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces a licensing and collaboration agreement with Munich-based SIRS Therapeutics and Vienna-based F4 Pharma to support the development of FX-06, a synthetic peptide that has a broad spectrum of potential indications. The partnership will ...

Improvement in lung function measured by oxygenation levels and markers for disease severity and lung fibrosis

Treatment with sargramostim was safe, well tolerated and generated T-cells targeted at the SARS-CoV-2 virus, indicating a COVID-19 specific immune response

Lexington, MA – February 26, 2021 /PRNewswire/ — Partner Therapeutics, Inc. (PTx) announced top-line results today of the investigator-led SARPAC (Sargramostim in Patients with Acute Hypoxic Respiratory Failure and Acute COVID-19) study of inhaled Leukine^® (sargramostim, yeast-derived recombinant human GM-CSF) in hospitalized COVID-19 patients ...

Studies Showed Statistically Significant Improvements in Survival in Subjects Treated with Leukine Starting 48 Hours After Acute, High Dose Radiation Exposure without Need for Blood Transfusions or Other Forms of Intensive Supportive Care 

Leukine Administration Starting 48, 72, 96 and 120 Hours after Lethal Radiation Exposure:

• • Enhanced Recovery of Platelets, Lymphocytes, Neutrophils and Reticulocytes
  • Reduced Frequency, Severity and Duration of Infection, Septicemia and Hemorrhage¹

 Studies Provided the Basis for FDA Approval of Leukine for Treatment of Myelosuppression and Hematopoietic Damage and Dysfunction ...

Experienced industry physician scientist to lead clinical development; Co-founder, Dr. Debasish Roychowdhury, to serve as Chief Technology Officer

Lexington, MA – September 15, 2020/ PR Newswire/ – Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, announced today its appointment of Edwin Rock, MD, PhD to serve as the company’s Chief Medical Officer. In his role as CMO, Dr. Rock will oversee clinical development activities for PTx, as well as serve on the Company’s executive leadership team.

Dr. Rock has ...

NCI sponsored, ECOG-ACRIN study advances after successful planned interim analysis

Lexington, MA – September 11, 2020 — Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces the resumption of enrollment in the National Cancer Institute (NCI) sponsored Study EA6141¹ being conducted by ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and led by Study Chair F. Stephen Hodi, MD, Director of the Center for Immuno-Oncology at Dana-Farber Cancer Institute and Study Co-Chair Ahmad Tarhini, MD, PhD., Professor of Oncologic Sciences and Director of Cutaneous ...

Study builds on extensive research showing that granulocyte-macrophage colony stimulating factor (GM-CSF) is needed for effective immune function in the lungs

iLeukPulm Phase 2 Clinical TrIal Supported by $35 Million Contract from U.S. Department of Defense

LEXINGTON, MA – August 25, 2020 — Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, announced today that the first patient has been enrolled in the iLeukPulm clinical trial, a randomized phase 2 study of inhaled Leukine (sargramostim, rhu-GM-CSF) in hospitalized COVID-19 patients with acute hypoxemia ...

Funding will support two randomized, multi-center clinical trials in COVID-19 patients, expansion of manufacturing capacity and potential Emergency Use Authorization (EUA) filing

LEXINGTON, MA – August 4, 2020 — Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, today anounced a $35 million milestone-based Other Transaction Agreement (OTA) with the U.S. Department of Defense (DOD) to fund two clinical studies of inhaled Leukine® (sargramostim, rhu-Granulocyte Macrophage-Colony Stimulating Factor “GM-CSF”) in patients with COVID-19 associated acute hypoxemia.  Through the DOD’s Chemical Biological Defense ...

LEXINGTON, MA. June 11, 2020 – Partner Therapeutics, a commercial biotechnology company, announces the enrollment of the first patient dosed in a Phase II investigator-initiated study evaluating the efficacy and safety of Leukine® (sargramostim, rhu-GM-CSF) in T cell replete HLA-mismatched haploidentical stem cell transplant recipients who are receiving post-transplant cyclophosphamide (NCT04237623).

The study will enroll patients with high risk hematologic malignancies who are the recipients of a haploidentical cell transplant. The trial will evaluate the effectiveness of Leukine compared to a matched ...

Trial expands global clinical research of Leukine in treatment of COVID-19 including multi-center trial underway in Belgium

Lexington, MA – May 28, 2020 — Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces the initiation of an investigator-initiated randomized, double-blind, placebo-controlled clinical trial of Leukine(sargramostim, rhu-GM-CSF) in patients with acute respiratory failure associated with COVID-19, conducted at Singapore General Hospital (NCT04400929).  The study will evaluate the effect of Leukine on lung function and other important patient outcomes.

“There is large ...

SARPAC trial initiated at the University Hospital Ghent in Belgium

Lexington, MA – March 24, 2020 /PRNewswire/ — Partner Therapeutics, Inc. (PTx) announced that Leukine^® (sargramostim, rhu-GM-CSF) is being assessed in the SARPAC trial (sargramostim in patients with acute hypoxic respiratory failure due to COVID-19 – EudraCT #2020-001254-22) at University Hospital Ghent to treat patients with respiratory illness associated with COVID-19.  Major medical centers in Germany, Italy and Spain are considering joining the study.  The study will evaluate the effect ...